Biotech Stocks in 2025: The High-Risk, High-Reward Play You Can’t Ignore

Wall Street's sleeping giant just woke up—and it's wearing a lab coat.

Biotech's make-or-break moment

FDA approvals are accelerating, gene-editing tech is maturing faster than ChatGPT, and Big Pharma's got $1.4 trillion burning holes in patent-expired pockets. Meanwhile, retail investors are still nursing crypto hangovers.

The smart money's already moving

Institutional inflows hit $9.2B last quarter—the highest since the mRNA vaccine gold rush. Short interest? Down 18% YTD. These stocks don't climb walls of worry; they CRISPR-edit them.

But here's the kicker

For every Moderna moonshot, there's a Theranos-grade implosion waiting to vaporize portfolios. The sector swings 37% more than the S&P 500 on average. Perfect for degenerates who think crypto's too stable.

Time to buy? Only if you enjoy playing Russian roulette with FDA approval letters.